A new paper published in Nature Biotechnology this week titled, “Template-independent enzymatic synthesis of RNA oligonucleotides,” provides details of a method for synthesizing single-stranded RNA ...
While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...
From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as their use continues to grow, so does a fundamental challenge: producing RNA ...
RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste.
RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, ...
From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as their use continues to grow, so does a fundamental challenge: producing RNA ...
tRNAs have a distinct cloverleaf secondary structure and an L-shaped tertiary structure. The cloverleaf structure is formed by the folding of the single-stranded tRNA molecule, which is typically ...
While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results